Response to dexamethasone in patients with fluid retention after docetaxel [9]

Lancet

Volumn 347, Issue 9013, 1996, Pages 1486-1487

  Chan, S ^a   Winterbottom, L ^a   Gardner, S ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL;

BODY WEIGHT; BREAST CANCER; CASE REPORT; DIURESIS; DRUG ACTIVITY; EDEMA; FEMALE; FLUID RETENTION; HUMAN; LETTER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030014894     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91723-7     Document Type: Letter

References (3)

1. Ca Hudis Ad Seidman Jpa Crown Phase 11 and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer J Clin Oncol 14 1996 58 65
2. Pm Ravdin Ha Burris III G. Cook Phase 11 trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 13 1995 2879 2885
3. V. Valerio Fa Holmes Rs Walters Phase 11 trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer J Clin Oncol 13 1995 2886 2894